Empowering precision oncology with one comprehensive test

Isabl integrates the whole genome and transcriptome to inform cancer care

We unlock the potential of the whole genome and transcriptome in cancer

Current approaches that sequence panels of cancer-associated genes have been adopted in clinical practice to guide tailored treatments. However, these tests evaluate a fraction of a cancer's genome and focus only on the most common actionable mutations.

Isabl GxT™ analyzes 100% of the genome and transcriptome to comprehensively identify clinically relevant mutations that were previously inaccessible. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.

Standard of Care

Leadership Team

A company with a passion to bring the future of genomic medicine to oncology today.

Elli Papaemmanuil

Elli Papaemmanuil

PhD, CEO and Scientific Co-founder

Juan Medina

Juan Medina

CTO and Technical Co-founder

Andrew Kung

Andrew Kung

MD PhD, Medical Co-Founder

Our journey

Logo Memorial Logan Kettering Cancer CenterLogo Two Sigma VenturesLogo Y Combinator

Isabl Inc. spun off from Memorial Sloan Kettering Cancer Center in 2020 and has been funded by Two Sigma Ventures, Y Combinator, and others.

The future of cancer genomics, today.

Contact us for partnering opportunities

Contact us